We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy
The 2026 Biophysics Congress was recently held in Hainan, where Clickmab presented its proprietary Click.mAb. AI antibody R&D platform and shared its technical explorations in epitope-specific de novo design, affinity maturation, and humanization. During the congress, Zhang Hong, academician of the Chinese Academy of Sciences and president of the Chinese Biophysical Society, visited Clickmab's booth for an in-depth exchange.
Recently, the 2026 Biophysics Congress was held at the Boao Forum for Asia International Conference Center in Hainan. Themed "Biophysics and Human Health," the congress brought together experts and scholars from life sciences, biophysics, and artificial intelligence for in-depth exchanges on frontier technology advances and applications in life and health sciences.
As a technology-driven biotech company focused on AI-powered antibody R&D innovation, Clickmab presented at the congress, showcasing its proprietary Click.mAb. AI antibody R&D platform and related technical achievements, and sharing its explorations and practices in applying AI to antibody drug R&D across epitope-specific de novo design, affinity optimization, and humanization.
During the congress, Zhang Hong — academician of the Chinese Academy of Sciences, president of the Chinese Biophysical Society, and chair of the congress organizing committee — visited Clickmab's booth for an in-depth exchange with the team on AI antibody design technologies and their applications in antibody drug R&D.
Academician Zhang Hong (2nd from left) visits Clickmab's booth
Traditional antibody discovery typically relies on experimental strategies such as animal immunization and phage display, obtaining candidate molecules by constructing antibody libraries and conducting large-scale screening. However, for certain targets with low immunogenicity, cryptic epitopes, or conformation-dependent structures, traditional methods often face challenges such as difficulty in candidate acquisition and insufficient epitope control.
Systemic Blind Spots in Traditional Methods
In the "AI Biology: New Paradigms and Applications" forum, Dr. Tianyuan Wang, CEO of Clickmab, delivered a keynote titled "Epitope-Specific AI De Novo Antibody Design for Antibody Drug R&D: Technical Principles, Current Applications, and Breakthrough Strategies."
Dr. Tianyuan Wang presenting on-site
The keynote centered on epitope-specific AI de novo antibody design technology, introducing how antigen structural information, target epitope characteristics, and generative AI algorithms can be combined to explore antibody candidate design directed at target regions, while sharing practical explorations of combining AI design with experimental validation to drive innovation in antibody R&D — offering a new technical pathway for antibody development against complex targets.
By combining computational design with structural analysis, AI technology is driving antibody R&D from the traditional "experimental screening-driven" model toward a "computational design and experimental validation synergy" model.
Clickmab's Precise Control over Epitopes
During the congress, Clickmab showcased its proprietary Click.mAb. AI antibody R&D platform. Built around the entire antibody R&D process, the platform integrates generative AI, structural computation, and intelligent research agent capabilities, supporting multiple R&D stages from target analysis, epitope design, and candidate generation to affinity optimization, humanization, and developability assessment.
To date, the Click.mAb. platform has been explored for applications including:
· Epitope-specific AI de novo antibody design
· Antibody affinity maturation
· CDR diversity design
· mAb and nanobody humanization
· Antibody developability analysis
· Structure prediction and supporting analysis
By combining AI computational capabilities with research workflows, the platform is committed to helping R&D teams improve antibody design efficiency, lower exploration costs, and provide more evidence to support decision-making on candidate molecules.
During the congress, Clickmab engaged in in-depth exchanges with experts and scholars from universities, research institutions, and industry, jointly exploring new opportunities at the intersection of artificial intelligence, biophysics, and drug development.
As generative AI, structural biology, and computational biology continue to advance, AI is increasingly becoming an important tool for life science research. Clickmab will continue to explore the deep integration of AI and antibody R&D, driving the application of intelligent technologies in biopharmaceutical R&D and providing new technical support for next-generation antibody drug innovation.
We look forward to advancing hand in hand, together driving AI to ignite a new future for modern antibody R&D!
Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.